NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

Event Calendar

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

MSCA Cofund 2025 Call webinar

FEB
Fri
14
14:00 - 16:10

Starts in 1 month from now

Location

virtual

Programmes

This webinar on the Marie Skłodowska-Curie Actions (MSCA) Cofund 2025 call is organised by the National Contact Points (NCPs) for MSCA in Belgium NCP Flanders, NCP-FNRS and NCP Federal BE.

The MSCA Cofund action provides complementary funding for new or existing doctoral programmes or postdoctoral programmes at regional, national and international level. Its aim is to spread the MSCA policies based on the European Charter for Researchers, including international, inter-sectoral and interdisciplinary research training and international and cross-sectoral mobilty of researchers in all stages of their career. The MSCA Cofund 2025 call is expected to open on the 23 January with a deadline on 24 June 2025.

During this webinar the objectives of Cofund, call modalities and hands-on information on the application submission and evaluation process will be provided, complemented by the perspectives from a partner in a MSCA Cofund and an expert evaluator. Furthermore an overview of the services of the Marie Curie Alumni Association (MCAA) will be presented (TBC).

Participation to this webinar is free and open to researchers and staff members willing to apply with a Belgian institution from the academic and non-academic sectors including industry, businesses, SMEs, public administration, civil society organisations, etc. Registration is required. The registration form offers the possibility to write any question for the speakers you might have at this stage.

The registration form is available on the event webpage.

Programme

14.00 Welcome and support services

14.10 Modalities of the MSCA Cofund 2025 call

  • Marc Patuzzo, project advisor and call coordinator, European Commission, Research Executive Agency

14.40 Questions and Answers

15.10 Perspectives from a laureate of a Cofund call and Questions and Answers

  • Alexander Botzki, Vlaams Instituut voor Biotechnologie (VIB), PULSE and Arise2 funded under the 2023 call

15.30 Perspectives from an Expert Evaluator and Questions and Answers

  • Eva Martin, Universitat Pompeu Fabra (UPF) Barcelona Spain

15.50 Marie Curie Alumni Association (MCAA) overview of services and Questions and Answers

  • Speaker TBC

16.10 Closure of the meeting

 

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.